Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  pertuzumab
Find trials that include:  Any drugs shown
Results 1-20 of 20 for your search:
Start Over
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: BO25126, NCI-2012-00351, 2010-022902-41, BIG 04-11, TOC4939G, NCT01358877
A Study Comparing Kadcyla Plus Perjeta Treatment to Chemotherapy Combined With Herceptin Plus Perjeta in Patients With HER2-Positive Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BO28408, NCI-2014-01818, NCT02131064
Gemcitabine Hydrochloride, Trastuzumab, and Pertuzumab in Treating Patients with Previously Treated HER2-Positive Metastatic Breast Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MCC-17656, NCI-2014-01935, 14.01.0062, 280513, Genentech ML28939, ML28939, NCT02139358
Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Stage II-IV Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 12147, NCI-2012-02371, 105932, NCT01730833
Paclitaxel, Trastuzumab, and Pertuzumab before Surgery in Treating Patients with Inflammatory Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-497, NCI-2013-01110, ML28193, NCT01796197
Eribulin Mesylate, Trastuzumab, and Pertuzumab in Treating Patients with HER2-Positive Breast Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-163, NCI-2013-01826, 688097, 707389, NCT01912963
FDG-PET in Predicting Treatment Response in Patients with Newly Diagnosed Stage II-IV Breast Cancer Receiving Pertuzumab and Trastuzumab Prior to Surgery
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: TBCRC 026, NCI-2014-01543, NA_00080994, NA_00080994 / CIR00002510, NCI-2014-00245, NCT01937117
Trastuzumab and Pertuzumab Alone or in Combination With Hormone Therapy or Eribulin Mesylate in Treating Older Patients With Stage IIIB-IV HER2-Positive Breast Cancer
Phase: Phase II
Type: Treatment
Age: 60 and over
Trial IDs: GCC1303, NCI-2014-00874, 1303GCC, ML28192, NCT02000596
A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf, and Erivedge Treatment Targeted Against Certain Mutations in Cancer Patients
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: ML28897, NCI-2014-01811, NCT02091141
Trastuzumab Emtansine and Pertuzumab before Surgery in Treating Patients with HER2-Positive Stage II-III Breast Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-409, NCI-2015-00454, NCT02326974
An Extension Study of Trastuzuma Emtansine in Patients Previously Treated With Trastuzuma Emtansine
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: TDM4529g, NCI-2009-01154, BO25430, NCT00781612
Taselisib and Anti-HER2 Therapy in Treating Patients with Advanced HER2+ Breast Cancer
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 15-024, NCI-2015-00627, ML29407, NCT02390427
Trastuzumab, Pertuzumab, and Lapatinib Ditosylate in Measuring Kinome Response in Patients with HER2+ Breast Cancer Undergoing Surgery
Phase: No phase specified
Type: Diagnostic, Treatment
Age: 18 and over
Trial IDs: LCCC 1214, NCI-2014-01407, 13-1826, NCI-2014-00972, NCT01875666
Start Over